Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma
Ying Waeckerle‐Men(University of St.Gallen), Silke Gillessen(Ente Ospedaliero Cantonale), Roger von Moos(Kantonsspital Graubünden), Christel Böhme(University of St.Gallen), Burkhard Ludewig(University of Zurich), Thomas Cerny(University Hospital Bonn), M. Fopp(University of St.Gallen), Daniel Ackermann, Hans‐Peter Schmid(Stanford University), Marcus Groettrup(University of Konstanz)
Cited by 118
Related Papers
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
|Journal of Clinical Oncology|2011|1.3k
Fibroblasts as immune regulators in infection, inflammation and cancer
|Nature reviews. Immunology|2021|597
A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis
|Nature Medicine|2009|594
Comparison of Orally Administered Cannabis Extract and Delta-9-Tetrahydrocannabinol in Treating Patients With Cancer-Related Anorexia-Cachexia Syndrome: A Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial From the Cannabis-In-Cachexia-Study-Group
|Journal of Clinical Oncology|2006|409